Although the clinical relevance with the aforementioned cardiovascular chance factor alterations by tirzepatide will be assessed from the planned cardiovascular outcome study SURPASS-CVOT ( "style":"medical-trial","attrs": "text":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Examination indicated that tirze